目的 探讨宫瘤消胶囊联合屈螺酮炔雌醇片（Ⅱ）治疗子宫内膜异位症的临床疗效。方法 选取2017年2月-2018年11月在复旦大学附属妇产科医院就诊的108例子宫内膜异位症患者作为研究对象，按照随机数字表法分为对照组和治疗组，每组各54例。对照组于月经第5天开始口服屈螺酮炔雌醇片（Ⅱ），1片/次，1次/d，连续治疗28 d。治疗组在对照组基础上口服宫瘤消胶囊，4粒/次，3次/d。两组患者连续治疗3个月。观察两组的临床疗效，比较两组细胞因子水平、疼痛评分和包块直径。结果 治疗后，对照组和治疗组的总有效率分别为77.78%、92.59%，两组比较差异有统计学意义（P<0.05）。治疗后，两组的转化生长因子-β1（TGF-β1）、基质金属蛋白酶-3（MMP-3）、血管内皮生长因子（VEGF）、碱性成纤维细胞生长因子（bFGF）水平均明显降低，同组治疗前后差异有统计学意义（P<0.05）；且治疗后治疗组的TGF-β₁、MMP-3、VEGF、bFGF水平均明显低于对照组，两组差异有统计学意义（P<0.05）。治疗后，两组的痛经评分、性交痛评分、包块直径均显著降低，同组治疗前后差异有统计学意义（P<0.05）；且治疗后治疗组的痛经评分、性交痛评分、包块直径均显著低于对照组，两组差异有统计学意义（P<0.05）。结论 宫瘤消胶囊联合屈螺酮炔雌醇片（Ⅱ）治疗子宫内膜异位症具有较好的临床疗效，可改善患者疼痛状况，调节细胞因子水平，安全性较好，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Gongliuxiao Capsules combined with Drospirenone and Ethinylestradiol Tablets (Ⅱ) in treatment of endometriosis. Methods Patients (108 cases) with endometriosis in Gynecology and Obstetrics Hospital Affiliated to Fudan University from February 2017 to November 2018 were randomly divided into control and treatment groups, and each group had 54 cases. Patients in the control group were po administered with Drospirenone and Ethinylestradiol Tablets (Ⅱ) from the fifth day of menstruation, 1 tablet/time, once daily, treated for 28 d. Patients in the treatment group were po administered with Gongliuxiao Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the cytokine levels, the pain, and the mass diameter in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.78% and 92.59%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of TGF-β₁, MMP-3, VEGF and bFGF in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the cytokine levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05).After treatment, the dysmenorrhea score, the sexual pain score, the mass diameter in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Gongliuxiao Capsules combined with Drospirenone and Ethinylestradiol Tablets (Ⅱ) has clinical curative effect in treatment of endometriosis, can improve the pain condition of patients, and regulate the levels of the cytokine, with good safety, which has a certain clinical application value.

R984